Comparative effectiveness and safety of apixaban and rivaroxaban in cirrhosis and atrial fibrillation

被引：0
|
作者：
Simon, Tracey G. [1 ]
Zhang, Yichi [2 ]
Mastrorilli, Julianna [3 ]
Cervone, Alexander [3 ]
Lin, Kueiyu Joshua [2 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA USA
[2] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA USA
[3] Brigham & Womens Hosp, Boston, MA USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
143
引用
收藏
页码：56 / 57
页数：2
相关论文
共 50 条
  • [31] Effectiveness and safety of low-dose versus standard-dose rivaroxaban and apixaban in patients with atrial fibrillation
    Perreault, Sylvie
    Cote, Robert
    Dragomir, Alice
    White-Guay, Brian
    Lenglet, Aurelie
    Dorais, Marc
    PLOS ONE, 2022, 17 (12):
  • [32] Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
    Chan, Yi-Hsin
    See, Lai-Chu
    Tu, Hui-Tzu
    Yeh, Yung-Hsin
    Chang, Shang-Hung
    Wu, Lung-Sheng
    Lee, Hsin-Fu
    Wang, Chun-Li
    Kuo, Chang-Fu
    Kuo, Chi-Tai
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (08):
  • [33] EFFECTIVENESS AND SAFETY OF APIXABAN, RIVAROXABAN AND WARFARIN IN PATIENTS WITH ADVANCED CKD AND ATRIAL FIBRILLATION: A NATIONWIDE US COHORT STUDY
    Fu, Edouard
    Desai, Rishi
    Paik, Julie
    Kim, Dae
    Zhang, Yichi
    Mastrorilli, Julianna
    Cervone, Alexander
    Lin, Joshua
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I130 - I132
  • [34] Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
    Kjerpeseth, Lars J.
    Selmer, Randi
    Ariansen, Inger
    Karlstad, Oystein
    Ellekjaer, Hanne
    Skovlund, Eva
    PLOS ONE, 2019, 14 (08):
  • [35] Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study
    Jaksa, Ashley
    Gibbs, Liza
    Kent, Seamus
    Rowark, Shaun
    Duffield, Stephen
    Sharma, Manuj
    Kincaid, Lynne
    Ali, Ayad K.
    Patrick, Amanda R.
    Govil, Priya
    Jonsson, Pall
    Gatto, Nicolle
    BMJ OPEN, 2022, 12 (10):
  • [36] Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation: A Multinational Population-Based Cohort Study
    Lau, Wallis C. Y.
    Torre, Carmen Olga
    Man, Kenneth K. C.
    Stewart, Henry Morgan
    Seager, Sarah
    Van Zandt, Mui
    Reich, Christian
    Li, Jing
    Brewster, Jack
    Lip, Gregory Y. H.
    Hingorani, Aroon D.
    Wei, Li
    Wong, Ian C. K.
    ANNALS OF INTERNAL MEDICINE, 2022, 175 (11) : 1515 - +
  • [37] Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
    Harrington, Amanda R.
    Armstrong, Edward P.
    Nolan, Paul E., Jr.
    Malone, Daniel C.
    STROKE, 2013, 44 (06) : 1676 - +
  • [38] An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation
    Mantha, Simon
    Ansell, Jack
    THROMBOSIS AND HAEMOSTASIS, 2012, 108 (03) : 476 - 484
  • [39] Effectiveness and safety of apixaban, rivaroxaban and warfarin in patients with advanced kidney disease and atrial fibrillation: A nationwide US cohort study
    Fu, Edouard L.
    Desai, Rishi J.
    Paik, Julie M.
    Kim, Dae
    Zhang, Yichi
    Mastrorilli, Julianna
    Cervone, Alexander
    Lin, Kueiyu Joshua
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 10 - 10
  • [40] Direct Comparisons of Apixaban, Dabigatran and Rivaroxaban in Atrial Fibrillation
    Jansson, Martin U.
    Sjogren, Vilhelm
    Sjalander, Sara
    Renlund, Henrik
    Norrving, Bo
    Sjalander, Anders
    CIRCULATION, 2018, 138
12345